Global Chronic Myeloid Leukemia Epidemiology and Patient Flow Analysis - 2017

Global Chronic Myeloid Leukemia Epidemiology and Patient Flow Analysis - 2017

  • January 2017 •
  • Report ID: 4835026 •
  • Format: PDF
Fore Pharma announced the results of its Chronic Myeloid Leukemia patients study in a new report ‘Global Chronic Myeloid Leukemia Epidemiology and Patient Flow Analysis - 2017’.

The report provides insights into Chronic Myeloid Leukemia epidemiology, Chronic Myeloid Leukemia diagnosed patients, and Chronic Myeloid Leukemia treatment rate for top seven pharmaceutical markets. The study measures key indicators such as prevalence of Chronic Myeloid Leukemia derived from epidemiological analysis, percentage of patients diagnosed with Chronic Myeloid Leukemia, and percentage of patients treated with a therapy.

The study helps executives estimate Chronic Myeloid Leukemia market potential, assess unmet need, develop drug forecasting models, and build population-based health management frameworks. The information presented in this study is used to evaluate market opportunities, effectively identify target patient population, and align marketing decisions.

The report provides estimates and forecasts of Chronic Myeloid Leukemia prevalence, Chronic Myeloid Leukemia diagnosis rate, and Chronic Myeloid Leukemia treatment rate for the period 2016 - 2025. The information is presented by leading geographies including the US, Germany, France, Spain, Italy, UK, and Japan. The study design is based on interpretation and analysis of data collected from physicians via primary interviews, registries, scientific journals, literatures, government databases and other secondary sources.

Key Features of the Report:
- Chronic Myeloid Leukemia Patient Flow
- Chronic Myeloid Leukemia Prevalence
- Chronic Myeloid Leukemia Diagnosed Patients
- Chronic Myeloid Leukemia Treated Patients